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Abstract
Background: Electronic cigarettes (e-cigarettes) are heavily marketed and widely perceived as helpful for quitting
or reducing smoking intensity. We test whether ever-use of e-cigarettes among early adopters was associated with: 1)
increased cigarette smoking cessation; and 2) reduced cigarette consumption.
Methods: A representative cohort of U.S. smokers (N = 2454) from the 2010 Tobacco Use Supplement to the Current
Population Survey (TUS-CPS) was re-interviewed 1 year later. Outcomes were smoking cessation for 30+ days
and change in cigarette consumption at follow-up. E-cigarettes use was categorized as for cessation purposes
or for another reason. Multivariate regression was used to adjust for demographics and baseline cigarette
dependence level.
Results: In 2011, an estimated 12 % of adult U.S. smokers had ever used e-cigarettes, and 41 % of these reported use
to help quit smoking. Smokers who had used e-cigarettes for cessation were less likely to be quit for 30+ days at
follow-up, compared to never-users who tried to quit (11.1 % vs 21.6 %; ORadj = 0.44, 95 % CI = 0.2–0.8). Among
heavier smokers at baseline (15+ cigarettes per day (CPD)), ever-use of e-cigarettes was not associated with
change in smoking consumption. Lighter smokers (<15 CPD) who had ever used e-cigarettes for quitting had
stable consumption, while increased consumption was observed among all other lighter smokers, although this
difference was not statistically significant.
Conclusions: Among early adopters, ever-use of first generation e-cigarettes to aid quitting cigarette smoking
was not associated with improved cessation or with reduced consumption, even among heavier smokers.
Keywords: Electronic cigarettes, Smoking cessation, Smoking reduction
Background
E-cigarettes have been intensively marketed since 2010
resulting in widespread awareness [1–5] and a fifteen-
fold increase in sales between 2010 and 2014 [6, 7].
However, there is still little population-level evidence
describing the association of cigarette smoking behaviors
with e-cigarette use [8], and the role of e-cigarettes in
tobacco control remains controversial [9, 10]. Given that
few smokers quit successfully in any given year [11], it
has been hypothesized that e-cigarette use may lead to
reduced health risks, particularly for heavier smokers, by
helping them to either quit cigarettes completely or to
substantially reduce the number of cigarettes smoked
each day [12]. This is counterbalanced with concern that
widespread promotion of e-cigarettes may re-normalize
smoking behavior and potentially increase tobacco use
among youth [13–16]. The public health arguments
against promoting e-cigarette use include that the health
effects of long-term use are currently unknown [17], that
e-cigarette aerosol contains similar numbers of fine par-
ticles, including nanoparticles, as cigarettes [13], and
that aerosol may contain numerous toxicants including
carcinogenic formaldehyde [13, 17, 18].
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To date there is limited empirical evidence regarding
the effect of e-cigarette use on cigarette smoking behavior,
including smoking cessation [13]. A systematic review and
meta-analysis by Kalkhoran and Glantz [8] summarized
20 studies and concluded that cigarette smokers who used
e-cigarettes were 28 % less likely to quit smoking com-
pared to those who did not use e-cigarettes. Among these
20 studies, 15 were cohort studies with follow-up. Only
one published study used a national probability sample of
the US: Grana et al. [19] reported that cigarette smokers
in 2011 who used e-cigarettes were not more likely to
quit or reduce cigarette consumption by the 1-year
follow-up time-point.
In this paper we report findings from a longitudinal
subsample of the large nationally representative 2010–
2011 Tobacco Use Supplement to the Current Popula-
tion Survey (TUS-CPS), fielded during a time of rapid
uptake of e-cigarettes in the US population [20]. This
survey assessed ever-use of e-cigarettes as well as rea-
sons for use (for cessation, or for other purposes), and
also use of pharmaceutical cessation aids. We compared
the smoking characteristics between those who used e-
cigarettes for quitting and those who used pharmaceut-
ical aids for quitting. We used multivariate regression to
examine the associations of ever use of e-cigarettes and
use of pharmaceutical aids for smoking cessation and




The core CPS is a labor force survey conducted monthly
by the US Census Bureau from a nationally representa-
tive civilian, non-institutionalized adult sample, in which
households are interviewed for 4 consecutive months,
rested for 8 months, and then re-interviewed for another
4 months before exiting the sample. For the TUS portion
of the survey, an interview is attempted with all eligible
adults in the household. If unsuccessful in obtaining the
self-interview, a proxy interview is sought. The TUS-
CPS is funded by the U.S. National Cancer Institute and
has been conducted since 1992 approximately every 3–4
years, to provide a nationally representative cohort of
smokers and nonsmokers. The rotating panel design of
the CPS provided an overlapped longitudinal sample of
respondents to the May 2010 TUS survey (baseline) who
were re-interviewed in May 2011 (follow-up; n = 28,153).
This longitudinal subsample of the TUS-CPS uses self-
report respondents only. Sample survey weights are pro-
vided to account for the complex sampling design, under
coverage, and non-response in the overlap sample,
allowing nationally representative estimates for the U.S.
[21]. Data from the TUS-CPS contain no personal iden-
tifiers and are analyzed anonymously. The Institutional
Review Board at the University of California, San Diego
reviewed the study protocol and did not consider it to
be human subjects research.
Cigarette smoking measures
The TUS-CPS uses the standard national tobacco ques-
tions including “have you smoked at least 100 cigarettes
in your entire life?” to identify ever smokers, and “do
you now smoke cigarettes every day, some days, or not
at all?” to identify current smokers. Average number of
cigarettes smoked per day (CPD) was assessed. Change
in consumption was computed as follow-up CPD minus
baseline CPD, for continuing smokers. We classified
those who smoked at least 15 CPD as heavier smokers,
as in previous work [22].
Cessation behaviors at follow-up
A quit attempt was identified with the question “during
the past 12 months, have you stopped smoking for one
day or longer because you were trying to quit smoking?”
or “during the past 12 months, have you made a serious
attempt to stop smoking because you were TRYING to
quit – even if you stopped for less than a day?”. Those
who smoked fewer than 12 days in the past 30 days were
alternatively asked “during the past 12 months have you
tried to quit smoking completely?” Respondents who re-
ported smoking at baseline but said they now smoked
not at all at follow-up were asked “about how long has it
been since you completely quit smoking cigarettes”. We
use 30+ days cessation at the follow-up survey as an
early marker of successful cessation [23–25]. As a sensi-
tivity analysis, we used 30+ days cessation on the longest
quit attempt of the past 12 months [26, 27], which was
assessed by “during the past 12 months, what is the lon-
gest length of time you stopped smoking because you
were trying to quit”. These quit attempts lasting at least
30 days were analyzed in the sensitivity analysis.
Ever use of e-cigarettes
At follow-up, ever-users of e-cigarettes were identified
with the question “have you ever tried a product called
an electronic or e-cigarette, such as ‘Smoking Everywhere’,
‘NJOY’, or other brands?” Use for quitting was assessed by
the question “have you ever used e-cigarettes to help you
quit smoking cigarettes or quit using other tobacco
products?”
Use of pharmaceutical assistance at most recent quit
attempt
At follow-up, those who had made a quit attempt were
asked about use of the following products on the most
recent attempt: “a nicotine patch, a nicotine gum or
nicotine lozenge, a nicotine nasal spray or nicotine in-
haler?; a prescription pill, called Chantix or Varenicline?;
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a prescription pill, called Zyban, Bupropion, or Wellbutrin?
another prescription pill?”.
Other measures
We classified respondents into age groups (18–24 years,
25–34 years, 35–49 years, 50 years and older), as male
or female, as non-Hispanic White or other race/ethni-
city, and into four levels of educational attainment (less
than high school, high school, some college, college and
above). Using the question, “how soon after you wake up
do you typically smoke your first cigarette of the day?”
those who smoked within 30 min of waking were con-
sidered more dependent. Age of initiation <16 years
classified a respondent as an early initiator, assessed with
the question “how old were you when you first started
smoking cigarettes fairly regularly”.
Statistical methods
We described the demographic and smoking character-
istics among those who made any quit attempts, ever
used e-cigarettes, and ever used e-cigarettes for quit-
ting. Chi-squared tests were conducted to compare dif-
ferences by e-cigarette use status. We also compared
smoking characteristics by e-cigarette and pharmaceut-
ical aid use status. We used multivariate logistic regres-
sion to examine the relationship of 30+ day cessation
at follow-up with ever use of e-cigarettes, and with use
of pharmaceutical aids at last quit attempt, adjusted for
baseline socio-demographic characteristics and nico-
tine dependence levels. E-cigarette use and use of
pharmaceutical aids were coded as main effects in an
additive model; these use categories are not mutually
exclusive. Statistical significance was assessed at the
two-sided 5 % level. All statistics were computed
using TUS-CPS overlap sampling weights according
to recommended procedures [21], using SAS 9.3 (SAS
Institute) survey procedures.
Results
In the longitudinal 2010–2011 TUS-CPS, there were
5255 baseline smokers who completed a self-reported
interview. Follow- up information was available one year
later on 3305 (62.9 %), however, only 2454 (46.7 %) com-
pleted the follow-up interview themselves (rather than
by proxy) and thus provided a detailed quitting history.
These 2454 baseline current smokers comprised the
current study sample.
Characteristics of the baseline sample
Table 1 summarizes the demographic and smoking
characteristics of the cohort as well as quit attempts
and e-cigarette use status. Of the baseline cigarette
smokers (N = 2454), 43.6 % made a quit attempt dur-
ing the one-year follow-up period (Table 1) and this
varied inversely with age (52.1 % to 40.0 %, youngest
to oldest). Lighter smokers were more likely to have
made a quit attempt than heavier smokers (48.7 % vs
37.3 %); those who smoked within 30 min of waking
were less likely to make a quit attempt than those
who did not (40.6 % vs 45.3 %).
Ever use of e-cigarettes
Of US smokers, an estimated 12.2 % reported ever
having used e-cigarettes in 2011 (Table 1). E-cigarette
use was higher among younger age groups (21.7 %
for those aged 18–24 years vs 14.1 % for ages 25–34
years, and lower percentages in older age groups),
and there was no gender difference. Ever-users were
more likely to be non-Hispanic White than from
other race-ethnic groups (13.8 % vs 7.1 %). Ever use in-
creased with attained educational level, from 7.4 % to
15.6 %. Heavier smokers were more likely to have used
than lighter smokers (15.1 % vs 9.9 %) and ever-users
were more likely to have initiated before age 16 years
than never-users (16.0 % vs 11.5 %).
Overall, 41.3 % of those who had ever used e-
cigarettes said the reason for use was to help quit smok-
ing. This percentage varied by age from a low of 31.0 %
for 18–24 years old users to almost half of ever-users
who were over age 35 years. Non-Hispanic whites were
more likely to have used e-cigarettes for quitting than
were other race-ethnic groups (42.5 % vs 33.6 %), as
were those with at least some college compared to those
with lesser education. Lighter smokers were less likely
than heavier smokers to have used for quitting. Those
who initiated smoking under age 16 years were more
likely to have used e-cigarettes for quitting than those
who initiated later (58.9 % vs 36.4 %). (Table 1).
Pharmaceutical aid use on most recent quit attempt
Of those with a quit attempt during the year, 20.1 % re-
ported using NRT and an additional 10.4 % reported
using Chantix. Only 3.1 % reported using Zyban and
0.5 % reported using any other pharmaceutical aid.
Among smokers who used any pharmaceutical aid,
16.0 % had quit for 30+ days at follow-up, with little
difference across type of pharmaceutical aid used. Ac-
cordingly, we used the combined category “any
pharmaceutical use” on the most recent quit attempt
for the remainder of this paper.
Baseline smoking characteristics by product use
Table 2 presents nicotine dependence characteristics by
e-cigarette and pharmaceutical aid use status, among
smokers with a quit attempt. As many smokers used
multiple cessation aids, the e-cigarette and pharmaceut-
ical aid use categories are not mutually exclusive.
Smokers who either used a pharmaceutical aid on their
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last quit attempt or had ever used an e-cigarette to quit
were more likely to be higher intensity smokers than
those who did not (14.1 CPD, pharmaceutical aid users;
14.9 CPD, e-cigarette ever-users who used for quitting;
<12 CPD, other categories). They were more likely to
smoke their first cigarette within the first 30 min after
waking and more likely to have initiated smoking by age
15 years than those who did not use either e-cigarettes
or pharmaceutical aids to quit.
Quit for 30+ days at follow-up, among those who tried
to quit
Among smokers who tried to quit, 21.6 % of those who
had never used e-cigarettes were quit for 30+ days at
follow-up, similar to the 22.4 % quit rate among those
who did not use a pharmaceutical aid in their last quit
attempt (Fig. 1). Ever use of an e-cigarette to quit was
associated with a lower success rate (11.1 %, Fig. 1) than
those who had not used an e-cigarette, and this differ-
ence was significant in an adjusted logistic regression
model (Table 3, ORadj = 0.4, 95 % C.I.: 0.2–0.8). Similarly,
smokers who used a pharmaceutical aid at last quit
attempt had a lower success rate (16.0 %, Fig. 1) than
those who did not (Table 3, ORadj = 0.7, 95 % C.I.: 0.5–0.9).
The success rate among those who ever used e-cigarettes
for cessation was observed to be substantially lower than
among those who used pharmaceutical aids at the last quit
attempt (Fig. 1). In a sensitivity analysis, the same model
using as outcome any cessation of 30+ days during the past
year had consistent results (Table 4) and the cessation ef-
fect associated with use of e-cigarettes was significantly less
than for use of pharmaceutical cessation aids.
Table 1 Past year quit attempts and ever use of e-cigarettes, by demographic characteristics, in a nationally representative cohort of
U.S. smokers; TUS-CPS 2010–11 longitudinal sample
N (%) Past- year quit
attempt (%)
Ever use of e-cigarettes
for any reason (%)
Ever use for
quitting (%)
Overall 2454 (100 %) 43.6 12.2 5.0
Age***
18–24 117 (13.3 %) 52.1 21.7 6.7
25–34 400 (18.0 %) 45.5 14.1 4.8
35–49 818 (30.3 %) 43.4 10.4 5.0
50 and above 1119 (38.3 %) 40.0 9.4 4.6
Gender
Female 1306 (46.6 %) 47.6 12.0 5.6
Male 1148 (53.4 %) 40.2 12.4 4.6
Race/Ethnicity***
Non-Hispanic White 2001 (76.2 %) 43.4 13.8 5.9
Other 453 (23.8 %) 44.3 7.1 2.4
Education**
Less than high school 383 (17.6 %) 42.6 7.4 2.6
High school 1005 (40.1 %) 42.5 12.0 4.7
Some college 740 (30.4 %) 47.0 13.9 6.4
College graduate 326 (11.9 %) 40.5 15.6 6.4
Cigarettes/day (cpd)***
< 15 1244 (53.5 %) 48.7 9.9 3.8
15+ 1175 (46.5 %) 37.3 15.1 6.6
Smoking < 30 min of waking
No 1514 (64.4 %) 45.3 11.5 4.6
Yes 890 (35.6 %) 40.6 13.6 6.1
Smoking before age 16***
No 2028 (83.3 %) 43.5 11.5 4.2
Yes 426 (16.7 %) 44.2 16.0 9.4
Note: P-values are from a chi-squared test across categories for differences in ever-use of e-cigarettes. Percentages are weighted to be representative of
the U.S. population
**p < 0.01, ***p < 0.001
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Change in cigarette smoking intensity over 12 months
Figure 2 presents change in cigarette consumption for
lighter and heavier smokers by categories of use of e-
cigarettes and pharmaceutical aids, separately for
those who made a quit attempt and who did not.
Among heavier smokers (15+ CPD) who did not
make a quit attempt, all decreased their consumption
over the year by 2.1 to 2.8 CPD, a regression-to-the-
mean phenomenon. Heavier smokers who reported a
quit attempt during the year decreased their con-
sumption by 3.7–5.2 CPD and the largest decline was
observed among those who reported no use of either
e-cigarettes or pharmaceutical aids, although the dif-
ference between these groups was not significant.
Among lighter smokers (<15 CPD) who did not make
a quit attempt, cigarette smoking consumption in-
creased over the year (+2.5–4.3 CPD), again as ex-
pected from regression-to-the-mean. A similar pattern
was seen among light smokers who made a quit at-
tempt (+2.0–4.3 CPD), with the exception of those
who ever-used e-cigarettes to quit. This group did
not increase cigarette smoking consumption over the
one-year follow-up period (change = −0.6 CPD, 95 %
CI = −1.9–0.7), although again the difference between
groups was not statistically significant. Multivariate linear
regression adjusted for baseline characteristics provides
consistent results (available upon request).
Discussion
This is the first longitudinal study to use a nationally
representative sample of U.S. smokers to provide evi-
dence regarding the impact of e-cigarettes on smoking
behavior at the U.S. population level. This study, con-
ducted before e-cigarettes were widely used, did not find
evidence that the ever-use of e-cigarettes as a cessation
aid among these early adopters was associated with
increased 30+ day smoking cessation at one-year follow-
up. Further, reported ever use of e-cigarettes by heavier
smokers was not associated with reduced cigarette
consumption at follow-up. However, among lighter
smokers, those who had ever used e-cigarettes for cessa-
tion had stable consumption levels, whereas all other light
smokers showed increased consumption at follow-up, al-
though these differences were not statistically significant.
In this study, those who had ever used e-cigarettes to
quit or had used pharmaceutical aids on their most re-
cent quit attempt equally appeared to be heavier, more
dependent smokers. Such a finding is well known for
pharmaceutical aids [28]. Thus, it was expected that suc-
cess rates for e-cigarette users and for pharmaceutical aid
users might be less than for non-users in this population
study, as we found to be the case in both adjusted and
unadjusted analysis. However, the data also suggest that
cessation rates among those who had used e-cigarettes for
quitting may be lower than cessation rates seen with use
of a pharmaceutical aid.
While our study is the first which can provide nationally
representative estimates for the U.S and focuses on early
adopters who used first generation e-cigarettes, it supports
results from the other published U.S. population-based
longitudinal cohort study [19], as well as the summary
results in meta-analysis across all 20 studies published as
of this writing [8]. Most recently, a Canadian study of
smokers enrolled in cessation assistance in the primary
care setting showed association of e-cigarette use with
poor cessation outcomes [29], consistent with our results.
In contrast, relying on samples in two U.S. metropolitan
areas Biener et al. [23] reported a strong association of
smoking cessation with daily use of e-cigarettes for 30+
Table 2 Baseline smoking characteristics by product use, among those who made a quit attempt; TUS-CPS 2010–11 longitudinal sample








at last quit attempt
No use of pharma aids
at last quit attempt
Sample size 82 58 936 356 720
Cigarettes smoked/day (CPD) 14.9 11.5 11.8 14.1 11.1
Time to 1st cigarette < 30 min from waking (%) 44.8 38.7 31.6 41.7 29.5
Duration of Cigarette Use (years) 23.5 20.2 24.6 26.7 23.2
Smoking Before Age 16 (%) 29.3 20.9 15.4 24.5 13.7
Note: E-cigarette use status and pharmaceutical aid use status are not mutually exclusive. All data weighted to be representative of the U.S. population
Fig. 1 Percentage of smokers with 30+ day cessation at follow-up,
among those who made a quit attempt
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days, as compared to non-users. However, most (66 %) of
those reporting daily e-cigarette use had adopted e-
cigarettes because they wanted to quit smoking, whereas
non-users did not report the same motivation, and the
resulting confounding by reverse causation can account
for the reported association. Indeed, to control for such
confounding in our study, we compared use and non-use
of cessation aids only among those who had tried to quit,
as in prior work [26, 27, 30, 31]; without this careful
choice of comparison group, we are able to replicate a
spurious association which is similar in magnitude to that
reported by Biener et al. [23] (data available upon request).
However, our study is unable to address whether extensive
and heavy use of e-cigarettes might facilitate cessation, as
we were unable to find such users in the national popula-
tion. As e-cigarette use moves beyond early adopters into
the population and product innovation continues, such
heavy use may become more common allowing the
Table 3 Logistic regression for 30+ day cessation at follow-up,






E-cigarette ever use status
Never used 34.9 Reference
Ever used to quit 17.3 0.4 0.2–0.8**
Ever used other than
to quit
30.4 0.7 0.4–1.5
Pharmaceutical aid used for last quit attempt
No 34.7 Reference
Yes 29.5 0.7 0.5–0.9**
Age
18–24 40.6 Reference
25–34 38.8 1.5 0.9–2.6
35–49 30.2 0.7 0.4–1.2
50+ 29.3 0.8 0.5–1.4
Sex
Female 33.9 Reference
Male 32.4 1.1 0.8–1.4
Race/Ethnicity
Non-Hispanic White 32.6 Reference
Other 35.0 1.0 0.7–1.3
Education
Less than high school 20.9 Reference
High school 32.1 2.2 1.4–3.4***
Some college 40.5 4.0 2.6–6.1***
College gradate 34.4 3.2 1.9–5.5***
Cigarettes smoked per day
< 15 36.2 Reference
15+ 28.9 1.0 0.7–1.2
Time to 1st cigarette < 30 min from waking
No 34.2 Reference
Yes 31.5 0.9 0.7–1.2
Smoking initiated before age 16 years
No 32.3 Reference
Yes 37.4 1.2 0.8–1.7
**p < 0.01, ***p < 0.001 All data is weighted to be representative of the
U.S. population
Table 4 Sensitivity analysis: logistic regression for any 30+ day
cessation during the past year, reported at follow-up, among






E-cigarette ever use status
Never used 21.6 Reference
Used to quit 11.1 0.3 0.2–0.5***
Used other than to quit 17.8 0.7 0.4–1.3
Pharmaceutical aid used for last quit attempt
No 22.4 Reference
Yes 16.0 0.8 0.6–1.1
Age
18–24 22.6 Reference
25–34 31.3 0.9 0.5–1.4
35–49 16.1 0.6 0.4–1.1
50+ 17.5 0.6 0.4–1.0
Sex
Female 20.0 Reference
Male 21.1 1.0 0.8–1.2
Race/Ethnicity
Non-Hispanic White 20.9 Reference
Other 19.2 1.2 0.9–1.6
Education
Less than high school 9.1 Reference
High school 17.6 2.0 1.4–2.7***
Some college 28.6 2.7 1.9–3.8***
College gradate 24.5 2.2 1.4–3.5***
Cigarettes smoked per day
< 15 22.5 Reference
15+ 17.8 0.8 0.6–1.0*
Time to 1st cigarette < 30 min from waking
No 22.2 Reference
Yes 17.4 1.1 0.8–1.4
Smoking initiated before age 16 years
No 20.4 Reference
Yes 21.3 1.4 1.1–1.8*
*p < 0.05, ***p < 0.001 All data is weighted to be representative of the
U.S. population
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association with cessation to be further tested [6, 32]. Our
observation that use of e-cigarettes by light smokers ap-
peared to prevent increased consumption by follow-up
was not hypothesized prior to this study. Thus, it is a
hypothesis-generating observation in need of replication.
Our study has a number of limitations. The survey
was conducted when e-cigarette use was uncommon but
rapidly increasing in the US. Accordingly, the e-cigarette
question at follow-up only sought information on ever-
use, as well as whether the use was for cessation. Ideally,
the usage report would have been linked directly to the
most recent quit attempt. However, in 2009 ever use of
e-cigarettes among smokers was less than 2 %, and 40 %
of ever-users also reported past 30-day use [4, 33]. Thus
we expect that most reported use fell within the past
year, as did the quit attempt. However, these findings
need to be replicated in other nationally representative
longitudinal studies. Although the diversity of e-cigarette
products was much smaller in 2010–2011 than at
present [32], the TUS-CPS treated e-cigarettes as a sin-
gle homogeneous product and there was no information
on intensity of use, whereas others have noted substan-
tial variability in nicotine levels, patterns of use and cus-
tomer experiences [34–36]. In the future it will be
important to investigate patterns of cigarette use among
sub-populations of e-cigarette users.
Conclusions
Among early adopters of first generation products,
ever-use of e-cigarettes to aid cigarette smoking
cessation was not associated with either improved
cessation outcomes or with reduced cigarette con-
sumption, in the U.S. population. The data also sug-
gested that cessation rates among those who had
used e-cigarettes for quitting may be lower than ces-
sation rates seen with use of a pharmaceutical aid in
the U.S. Thus, this study suggests that it is prema-
ture to conclude that e-cigarettes will be helpful to
smokers who make a quit attempt. It also seems pre-
mature to conclude that e-cigarettes will be an ef-
fective way for smokers, especially heavy smokers, to
reduce the number of cigarettes that they smoke
each day. Given the intensive marketing and rapid
increase in use of e-cigarettes, it will be important to
study advertising content as well as smokers’ atti-
tudes and beliefs regarding these products, in order
to assess the role of e-cigarettes in changing smoking
behavior.
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